IceCure Medical Secures US Patent for XSense Cryoprobes
Ticker: ICCM · Form: 6-K · Filed: Sep 18, 2025 · CIK: 1584371
Sentiment: bullish
Topics: patent, medical-device, intellectual-property
TL;DR
IceCure Medical just got a US patent allowance for their new XSense cryoprobes - big win for their tech!
AI Summary
On September 18, 2025, IceCure Medical Ltd. announced it received a Notice of Allowance for a U.S. Patent for its next-generation XSense™ Cryoprobes. This patent covers a novel method for cryoablation procedures, enhancing the company's intellectual property portfolio in the medical device sector.
Why It Matters
This patent allowance strengthens IceCure's competitive position and protects its innovative cryoablation technology, potentially leading to increased market share and future product development.
Risk Assessment
Risk Level: low — This filing is a routine report of a patent allowance, which is generally positive news with low immediate risk.
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report and recipient of the patent allowance.
- XSense™ Cryoprobes (product) — The technology for which the U.S. Patent was allowed.
- September 18, 2025 (date) — Date of the press release and filing.
FAQ
What is the specific innovation covered by the U.S. Patent Notice of Allowance for the XSense™ Cryoprobes?
The filing states the patent covers a novel method for cryoablation procedures.
When was the press release regarding the patent allowance issued?
The press release was issued on September 18, 2025.
What form is this SEC filing?
This is a Form 6-K, Report of Foreign Private Issuer.
What is the principal executive office address for IceCure Medical Ltd.?
The address is 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504 Israel.
Does IceCure Medical Ltd. file annual reports under Form 20-F or Form 40-F?
IceCure Medical Ltd. files annual reports under Form 20-F.
Filing Stats: 315 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2025-09-18 08:35:08
Filing Documents
- ea0257813-6k_icecure.htm (6-K) — 12KB
- ea025781301ex99-1_icecure.htm (EX-99.1) — 10KB
- 0001213900-25-088783.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: September 18, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 3